Modified liposome and application thereof in preparation of mucosal vaccine

Through the administration of modified chitosan-modified liposome nasal drops, the problem that existing vaccines are difficult to induce mucosal immunity is solved, and efficient nucleic acid delivery and immune response activation is achieved, which is suitable for large-scale immunization.

CN118873684APending Publication Date: 2024-11-01SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410844820.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-27
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The existing vaccine administration methods are difficult to directly induce mucosal immunity, and there are local discomforts, immune differences and biological disorders in traditional intravenous, muscle and subcutaneous injections. The nasal mucosal vaccine is inefficient and difficult to overcome the effect of cilia layer removal.

Method used

The anionic liposome modified by modified chitosan is equipped with nucleic acids and nasal drop administration method is used to improve mucosal delivery efficiency and stimulate the triple immune response of humoral, cell and mucosal.

Benefits of technology

It realizes low toxicity, low immunogenicity, and high loading nucleic acid delivery, improves nucleic acid transfection efficiency, activates the immune system, induces high-level systemic and mucosal antibody responses, avoids discomfort and biological disorders caused by injection, and is suitable for large-scale Scale immunization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118873684A_ABST
    Figure CN118873684A_ABST
Patent Text Reader

Abstract

The invention discloses a modified liposome and application thereof in preparation of mucosal vaccines, and belongs to the technical field of biological medicines. The liposome is modified by the modified chitosan, the transmucosal delivery efficiency is improved, the transfection efficiency of nucleic acid and the expression quantity of a target antigen are improved, and triple immune reactions of body fluid, cells and mucous membranes can be initiated through nasal administration after nucleic acid carrying, so that an immune system is activated, high-level whole body and mucous membrane antibody reactions are induced, and the immune response of the whole body and mucous membranes is inhibited. And better cross protection is expected to be provided, so that invasion of external pathogens is prevented. The immune effect of the liposome is equivalent to that of the existing commercial liposome for intravenous injection or intramuscular injection, the modified liposome does not need injection administration, the preparation method is simple, the raw materials are cheap and easy to obtain, and the liposome shows a good industrial transformation prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a modified liposome and application thereof in preparing a mucosal vaccine, belonging to the technical field of biomedicine. Background Art

[0002] Compared with conventional vaccines, mRNA vaccines with strong immunogenicity, short R&D cycle and low production cost can provide more favorable support for epidemic prevention and control. Intravenous injection, intramuscular injection and subcutaneous injection are the most common direct administration routes in traditional active therapeutic mRNA vaccine trials. Intravenous injection can quickly activate systemic immune response, but because lipid nanoparticles (LNP) may be quickly cleared by macrophages in the liver, this limits its application in mRNA vaccines; intramuscular injection, subcutaneous injection and other methods may cause swelling and pain at the injection site, local infection and granuloma formation, and individual effects may also vary. At the same time, the above three methods all require injection, which may cause patients to fear and anxiety about needles; at the same time, medical staff are required to operate, which will undoubtedly consume medical manpower and supplies.

[0003] Mucosal vaccines have also become one of the hot spots in global vaccine research and development today. The mucosal immune system is an important component of the body's immune system, and it is also an independent immune system with unique structure and function. It plays an extremely important role in resisting external infections. Experiments have shown that after mucosal immunization, local antibodies in the mucosa appear earlier than serum antibodies, have higher titers and last longer, and can eliminate foreign pathogenic microorganisms before invading body tissues, avoiding damage to body tissues. However, existing methods of administering drugs through intravenous, subcutaneous, and intramuscular injections can often only induce humoral immunity and cellular immunity, and cannot directly induce mucosal immunity.

[0004] Traditional mucosal immunization vaccines are less efficient and are mainly used to fight intestinal pathogens. They are mostly administered orally. After reaching the digestive system, oral vaccines use intestinal mucosal structures such as Peyer's patches to recognize antigens and produce an immune response. Because the intestinal mucosal epithelial tissue secretes a large amount of mucus and forms a physical barrier to prevent foreign matter from being retained on the intestinal wall, oral vaccines need to overcome the mucosal barrier and the mucus physical barrier, while also considering the effects of gastric acid and digestive enzymes on antigen activity. Therefore, oral vaccines often require multiple vaccinations to induce a sustained immune response, and the pathogens they target are often mainly intestinal pathogens.

[0005] As an alternative to systemic vaccination, nasal mucosal vaccination is safer and more effective. It can induce specific immunoglobulin A (IgA), stimulate resident memory B and T cells in the nasal cavity and upper respiratory tract, and then produce a triple immune response of cellular immunity, humoral immunity and mucosal immunity. It plays an important role in effectively neutralizing upper respiratory tract viruses and helps prevent early infection and spread of pathogens. However, nasal mucosal vaccines are also affected by biological barriers (mucosal / mucus barrier). In addition to the nasal mucosal layer on the inner surface of the nasal cavity, the surface of the nasal mucosa is covered with cilia, which can move particles to the pharynx by swinging, thereby achieving clearance. Therefore, the construction of nasal mucosal vaccines needs to overcome the clearance effect of the ciliary layer, and at the same time, it needs to improve the strength and durability of mucosal immunity. So far, there is only one product on the market, and it is still necessary to develop efficient and safe nasal mucosal vaccines. Summary of the invention

[0006] To solve the above problems, the present invention provides a modified liposome and its application in the preparation of mucosal vaccines. The liposome is modified with modified chitosan, and the transmucosal delivery efficiency is improved. After carrying nucleic acid, it can induce a triple immune response of body fluids, cells, and mucosa by nasal drops, effectively preventing the invasion of external pathogens. The modified liposome described in this application does not require injection, and the preparation method is simple, the raw materials are cheap and easy to obtain, showing a good prospect of industrial transformation.

[0007] The first object of the present invention is to provide a modified liposome, wherein the outer surface of the liposome is modified with modified chitosan, the liposome is anionic liposome, and the modified chitosan is obtained by connecting sodium 8-(2-hydroxybenzamido)octanoate and chitosan through an amide bond.

[0008] Furthermore, the anionic liposome is a nano-scale particle, and the modification of the modified chitosan is achieved through the interaction between the liposome and the modified chitosan, including but not limited to electrostatic interaction.

[0009] Furthermore, the mass ratio of the anionic liposome to the modified chitosan is 1:0.5-2.

[0010] Furthermore, the molecular weight of the chitosan is in the range of 1000-5000000, and the degree of deacetylation is not less than 55%.

[0011] Furthermore, the anionic liposome contains at least two components of anionic lipids, phospholipids, polyethylene glycol lipids and cholesterol, and most preferably contains the above components simultaneously.

[0012] Furthermore, the anionic lipid is selected from one or more of distearoylphosphatidylglycerol (DSPG), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidic acid (DPPA) and distearoylphosphatidic acid (DSPA).

[0013] Furthermore, the phospholipid is selected from neutral phospholipids or cationic phospholipids.

[0014] Preferably, the phospholipid is 1-octylnonyl 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]octanoate (SM-102).

[0015] Furthermore, the polyethylene glycol lipid is selected from one or more of phospholipid polyethylene glycol (DSPE-PEG), phospholipid polyethylene glycol thiol (DSPE-PEG-SH), phospholipid polyethylene glycol amino (DSPE-PEG-NH), and phospholipid polyethylene glycol carboxyl (DSPE-PEG-COOH).

[0016] Furthermore, based on the molar percentage of the anionic lipids, phospholipids, polyethylene glycol lipids and cholesterol being 100 mol%, the proportion of each component is 5 mol%-15 mol%, 20 mol%-80 mol%, 0 mol%-5 mol%, 10 mol%-50 mol%.

[0017] The second object of the present invention is to provide a method for preparing the modified liposome, comprising the following steps:

[0018] S1. preparing liposomes;

[0019] S2, mixing chitosan with (carboxyl) activated 8-(2-hydroxybenzamido) sodium octanoate to react (to combine the amino group with the carboxyl group) to obtain modified chitosan;

[0020] S3, mixing the liposome obtained in S1 with the modified chitosan obtained in S2 to obtain the modified liposome.

[0021] Further, in step S3, liposomes are mixed with modified chitosan under pH 6-7.

[0022] Further, in step S3, liposome nanoparticles are obtained by shaking.

[0023] The third object of the present invention is to provide the use of the modified liposome in the preparation of mucosal vaccines.

[0024] Furthermore, the mucosa is nasal mucosa.

[0025] The fourth object of the present invention is to provide a delivery vehicle for nasal drugs, wherein the delivery vehicle comprises a modified liposome.

[0026] The fifth object of the present invention is to provide a nucleic acid vaccine, which contains modified liposomes and nucleic acid.

[0027] Furthermore, the nucleic acid vaccine is a mucosal nucleic acid vaccine administered transmucosally.

[0028] Furthermore, the transmucosal administration includes nasal administration.

[0029] Specifically, the nasal administration can be administered by nasal inhalation administration, nasal spray administration, nasal drops administration, etc.

[0030] Furthermore, the vaccine is a preventive vaccine or a therapeutic vaccine.

[0031] Furthermore, the preparation method of the nucleic acid vaccine is:

[0032] (1) preparing an aqueous phase solution and a lipid phase solution containing nucleic acid, and then preparing liposomes using the aqueous phase solution and the lipid phase solution;

[0033] (2) mixing chitosan with (carboxyl) activated 8-(2-hydroxybenzamido) sodium octanoate to react (to combine the amino group with the carboxyl group) to obtain modified chitosan;

[0034] (3) Mixing the liposomes and the modified chitosan to obtain the nucleic acid vaccine.

[0035] Furthermore, the liposomes in step (1) can be prepared by microfluidics.

[0036] Furthermore, the mass ratio of the modified liposome to the nucleic acid is 10-200: 1. Preferably, the mass ratio of the modified liposome to the nucleic acid is 15-60:1.

[0037] Furthermore, the nucleic acid may be DNA or RNA.

[0038] Furthermore, the RNA is selected from one or more of free short interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, microRNA (miRNA), antagomir, antisense RNA, ribozyme, Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA) and messenger RNA (mRNA).

[0039] Furthermore, the RNA encodes at least one antigen.

[0040] Furthermore, the antigen is selected from one or more of infectious disease antigens and autoimmune disease antigens.

[0041] Furthermore, the infectious disease antigen is selected from bacterial antigens, viral antigens, and fungal antigens.

[0042] Furthermore, the bacterial antigen is selected from one or more of Staphylococcus aureus antigen, Mycobacterium tuberculosis antigen, Bordetella pertussis antigen, Salmonella flagella protein, bacterial antigen, capsule antigen, and bacterial outer membrane protein.

[0043] Furthermore, the viral antigen is selected from one or more of influenza virus antigen, parainfluenza virus antigen, novel coronavirus antigen, respiratory syncytial virus antigen, rubella virus antigen, measles virus antigen, human immunodeficiency virus antigen, human papillomavirus antigen, varicella-zoster virus antigen, herpes simplex virus antigen, Epstein-Barr virus antigen, rhabdovirus antigen, rotavirus antigen, parvovirus antigen, picornavirus antigen, poliovirus antigen, mumps virus antigen, rabies virus antigen, hepatitis A virus antigen, hepatitis B virus antigen, hepatitis C virus antigen, hepatitis D virus antigen, and hepatitis E virus antigen.

[0044] The sixth object of the present invention is to provide a drug for preventing or treating infectious diseases, wherein the drug contains the modified liposome, delivery vector or nucleic acid vaccine, wherein the nucleic acid can be miRNA, siRNA or shRNA designed according to the target, or can be DNA or RNA encoding infectious disease antigens.

[0045] Furthermore, the infectious diseases include but are not limited to influenza, new coronavirus infection, pneumonia, tuberculosis, whooping cough, rubella, measles, chickenpox, poliomyelitis, viral hepatitis, etc.

[0046] Beneficial effects of the present invention:

[0047] 1) The modification of modified chitosan endows anionic liposomes with the ability to encapsulate nucleic acid drugs, enabling low toxicity, low immunogenicity, and high-load nucleic acid delivery.

[0048] 2) The modified liposomes have high mucosal permeability and retention rates. After nasal administration, they can effectively carry nucleic acid molecules through the mucosal barrier, improve the transfection efficiency of nucleic acids and the expression of target antigens, induce mucosal protective immune responses and mucosal systemic immune responses, increase the secretion of specific immunoglobulin A (IgA) and the activation of B cells and T cells, and can simultaneously activate the triple immune responses of humoral immunity, cellular immunity and mucosal immunity, thereby activating the immune system and inducing high levels of systemic and mucosal antibody responses, which is expected to provide better cross-protection and effectively prevent the invasion of external pathogens.

[0049] 3) The mucosal nucleic acid vaccine can be administered through the nasal mucosa, is non-invasive and injection-free, and has a similar efficacy to commercial liposomes injected intramuscularly, avoiding the risk of blood-borne infection due to needle reuse, while allowing more frequent booster vaccinations. It is helpful for large-scale immunization in pandemic situations, and is particularly helpful in overcoming barriers to vaccination in low-income or remote areas.

[0050] 4) The modified chitosan described in the present application is easy to obtain and easy to prepare. It can be modified onto the surface of anionic liposomes by simple mixing, which is easy to control the cost. The reaction conditions are mild, which is conducive to expanding production. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 is a schematic diagram of the preparation and use of the nasal mucosal vaccine of the present invention;

[0052] Figure 2 is the calculated permeability result of each group in Example 2;

[0053] Figure 3 are confocal microscopic images of mucosal tissue sections of each group in Example 3;

[0054] Figure 4 is the test result of bioluminescence intensity of each group in Example 4;

[0055] Figure 5 is a statistical graph of OVA-specific IgG antibody titers in the peripheral blood of each group of mice in Example 5.1;

[0056] Figure 6 The CD4 positive cells of interferon-γ (IFN-γ) in the spleen of each group of mice in Example 5.2 + Helper T cells (CD3 + CD4 + IFN-γ + )'s relative content statistics;

[0057] Figure 7 The CD8 positive cells of interferon-γ (IFN-γ) in the spleen of each group of mice in Example 5.2 + Cytotoxic T cells (CD3 + CD8 + IFN-γ + )'s relative content statistics;

[0058] Figure 8 This is a statistical graph of the OVA-specific IgA antibody titer in the nasal mucosal lavage fluid of each group of mice in Example 5.3. DETAILED DESCRIPTION

[0059] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0060] The above and other technical contents, features and effects of the present invention will be clearly presented in the following detailed description of the preferred embodiments with reference to the drawings. Through the description of the specific implementation methods, the technical means and effects adopted by the present invention to achieve the predetermined purpose can be more deeply and specifically understood. However, the drawings are only for reference and explanation purposes and are not used to limit the present invention.

[0061] As used herein, "transfection" refers to the introduction of a substance (eg, RNA) into a cell. Transfection occurs in vitro or in vivo.

[0062] The experimental materials used in the examples are as follows:

[0063]

[0064]

[0065] Description of the detection instruments, detection methods, detection parameters, and kits used in the examples:

[0066] Liposome synthesis equipment: Myana rapid nano drug preparation system INano L

[0067] Particle size detection instrument: Nano particle size and zeta potential instrument, model Nano ZS (Malvern).

[0068] Average particle size: The samples were tested using a nanometer particle size and zeta potential instrument, model Nano ZS (Malvern), and the Z-average value given by the instrument was recorded.

[0069] In vitro transmucosal research device: drug vertical diffusion tester RYJ-12B (Huanghai Drug Testing)

[0070] Example 1: Preparation of modified chitosan-modified liposome nanoparticles

[0071] Example 1.1: Preparation of liposome nanoparticles

[0072] Preparation of lipid phase solution: Phospholipid SM-102, phospholipid polyethylene glycol thiol (DSPE-PEG-SH, 2000MW), anionic lipid distearoylphosphatidylglycerol (DSPG), and cholesterol were dissolved in anhydrous ethanol. The concentrations of each component in the lipid phase solution are shown in Table 1.

[0073] Table 1: Lipid phase solution formulation

[0074] Component name concentration SM-102 5mM DSPE-PEG-SH 0.15mM DSPG 1mM cholesterol 3.85mM

[0075] Preparation of aqueous solution: Dissolve 1.24 g of citric acid and 1.21 g of trisodium citrate in 100 mL of DEPC (diethylpyrocarbonate) treated water to obtain a citrate DEPC buffer with a pH of 4 and a concentration of 100 mM. Dissolve mRNA in the above citrate DEPC buffer to obtain an aqueous solution with an mRNA concentration of 100 μg / mL.

[0076] The synthesis of liposome nanoparticles was carried out by microfluidics technology, and the specific device used was the Myana Rapid Nanodrug Preparation System (trade name INano TM L), the preparation process is as follows: the lipid phase solution and the aqueous phase solution are loaded into the sample pool respectively, and the flow rate is controlled by setting the program so that the lipid phase enters the microfluidic device at a constant flow rate of 3 mL / min and the aqueous phase at a constant flow rate of 9 mL / min (the flow rate ratio of the lipid phase to the aqueous phase is 1:3) and is mixed to obtain a suspension containing the product liposome nanoparticles.

[0077] After the reaction is completed, the suspension is mixed with PBS solution at a volume ratio of 1:5, and the product liposome nanoparticles (LNP) are collected by ultrafiltration through an ultrafiltration tube (with a retention rate of 30 kD). The color of the product liquid is white with opalescence.

[0078] The particle size distribution and charge of the product LNP were detected by Zeta potential instrument. The results showed that its particle size was about 100nm, and the potential test results showed that the above LNP was negatively charged. This shows that anionic liposomes with uniform particle size were successfully synthesized and can be further modified.

[0079] Example 1.2: Preparation of modified chitosan

[0080] 1 gram of chitosan (50 kD, deacetylation degree>90%) was completely dissolved in 100 ml of 0.1 M hydrochloric acid solution, and the mixed solution was adjusted to 5-7 with sodium hydroxide solution to obtain a chitosan solution.

[0081] Sodium 8-(2-hydroxybenzamido)octanoate (SNAC), EDC and N-hydroxysuccinimide (NHS) were weighed separately and dissolved in 20 mL of anhydrous dimethyl sulfoxide, wherein the molar ratio of the carboxyl group of SNAC to EDC and NHS was 1:1.5:1.5, and reacted at room temperature with magnetic stirring for 1 hour, maintaining the pH between 5 and 7 during the reaction, to obtain an activated intermediate solution.

[0082] The chitosan solution is mixed with the activated intermediate solution, and the reaction is continued for 48 hours at room temperature under magnetic stirring. After the reaction is completed, a final reaction solution is obtained, and the final reaction solution is filtered by sedimentation with anhydrous ethanol and then vacuum dried to obtain modified chitosan (SCS).

[0083] Example 1.3: Preparation of modified chitosan-modified liposome nanoparticles

[0084] Anionic liposomes and modified chitosan were prepared according to the method described in Example 1.1 and Example 1.2, respectively, and the two were mixed in a buffer solution of pH=6.5 at different mass ratios, and shaken for 15 minutes to synthesize modified chitosan-modified liposome nanoparticles (SCS-LNP). The particle size of the modified chitosan-modified liposome nanoparticles synthesized at different mass ratios was tested, and the results are shown in Table 2.

[0085] Table 2: Particle size test results of modified chitosan-modified liposome nanoparticles prepared in different embodiments

[0086] Example No. Anionic liposome concentration Modified chitosan concentration Average particle size (nm) / PDI Example 1.3.1 1mg / mL / 102.58 / 0.032 Example 1.3.2 1mg / mL 4mg / mL 1000 / 1.185 Example 1.3.3 1mg / mL 2mg / mL 486.27 / 0.226 Example 1.3.4 1mg / mL 1mg / mL 220.75 / 0.085 Example 1.3.5 1mg / mL 0.5mg / mL 273.69 / 0.11 Example 1.3.6 1mg / mL 0.25mg / mL 892.57 / 0.495

[0087] The particle size test results show that the particle size of the product changes significantly after adding modified chitosan. The particle size of the product in Example 1.3.2-Example 1.3.6 is different from that in Example 1.3.1. The positively charged SCS can be modified to the surface of the anionic LNP through electrostatic interaction, which may lead to an increase in the particle size of the liposome. Among them, although the particle size of the SCS-LNP synthesized under the mass ratio described in Example 1.3.2 and Example 1.3.6 is larger, its structure is also stable; in addition, the particle size of the SCS-LNP prepared in Example 1.3.3-Example 1.3.5 is slightly smaller and more uniform, which is expected to be more conducive to the delivery of nucleic acids and uptake by cells.

[0088] Control Example 1.4: Preparation and testing of commercial liposomes

[0089] According to the method described in Example 1.1, Moderna commercial liposomes (Moderna LNP) were prepared. As commercially used liposomes, the liposomes can carry nucleic acids and deliver vaccines in vivo, and can be used as a reference to verify the effect of the liposomes described in this application. The aqueous phase for preparing commercial liposomes in this example is the same as that in Example 1.1, and the lipid phase solution formula is shown in Table 3:

[0090] Table 3: Formulation of commercial liposome lipid phase solution

[0091] Component name concentration SM-102 5mM <![CDATA[PEG 2k -DMG]]> 0.15mM DSPC 1mM cholesterol 3.85mM

[0092] The charge of the product Moderna LNP was detected by a Zeta potential instrument, and the results showed that it carried a positive charge.

[0093] Moderna LNP and SCS were mixed and shaken in a buffer solution of pH = 6.5 at a mass ratio of 1:1 for 15 minutes, and the mixed product was collected. The particle size test was performed on Moderna LNP, SCS and the mixed product, respectively. The results are shown in Table 4.

[0094] Table 4: Particle size test of commercial liposomes before and after modification with modified chitosan

[0095] Test subjects Average particle size (nm) Moderna LNP 99.02 SCS 846.15 Mixed solution of ModernaLNP and SCS 832.87

[0096] Since both Moderna LNP and SCS carry positive charges, the two cannot be assembled through electrostatic interaction, so SCS cannot be modified on the surface of Moderna LNP, that is, the particle size detection results of the mixed solution of Moderna LNP and SCS are close to the particle size detection results of SCS.

[0097] Example 2: Transmucosal efficiency of modified chitosan-modified liposome nanoparticles

[0098] Franz diffusion cell was used to conduct in vitro mucosal permeation study. The experimental method is as follows: fresh rat nasal mucosa is placed between the injection chamber and the receiving chamber, clamped with a clamp and tested for leaks. After confirming that the system is airtight, a PBS solution of liposome nanoparticles loaded with DiD dye is added to the injection chamber, and the receiving chamber is filled with isotonic PBS solution, which is placed in the system for constant temperature and continuous stirring. The liquid in the receiving chamber is collected at different time points, its fluorescence intensity is measured, and the same volume of PBS solution is replenished. The final permeability can be calculated by the following formula:

[0099] Permeability (%) = [V 0 C n +∑(V x C n-1 )] / A*100%

[0100] Among them, V 0 is the volume of the receiving chamber, C n is the concentration of DiD in the solution sampled at the nth time point, V x is the volume of each sample, C n-1 is the concentration of DiD in the sample solution at the previous time point (i.e., the n-1th time point), ∑(V x C n-1 ) represents the product of the DiD concentration in the sampled solution from the 1st time point to the n-1th time point and the volume of each sample, and A is the concentration of DiD in the administered solution. For this embodiment, V0 8mL, V x is 0.5mL.

[0101] The embodiments are grouped as follows:

[0102] Control Example 2.1: Liposome nanoparticles prepared according to the ratio described in Example 1.3.1, loaded with DiD dye;

[0103] Example 2.2: Liposome nanoparticles prepared according to the proportions described in Example 1.3.2, loaded with DiD dye;

[0104] Example 2.3: Liposome nanoparticles prepared according to the proportions described in Example 1.3.3, loaded with DiD dye;

[0105] Example 2.4: Liposome nanoparticles prepared according to the proportions described in Example 1.3.4, loaded with DiD dye;

[0106] Example 2.5: Liposome nanoparticles prepared according to the proportions described in Example 1.3.5, loaded with DiD dye;

[0107] Example 2.6: Liposomal nanoparticles prepared according to the proportions described in Example 1.3.6, loaded with DiD dye.

[0108] Control Example 2.7: A mixed solution of Moderna LNP and SCS prepared according to the method described in Control Example 1.4, with a mass ratio of 1:1, wherein Moderna LNP is loaded with DiD dye.

[0109] In Comparative Examples 2.1 to 2.7, the permeability calculation results at different time points are as follows: Figure 2 The results show that the mucosal permeability of Examples 2.2 to 2.6 is significantly higher than that of Control Example 2.1, indicating that the liposome nanoparticles modified with modified chitosan have a good transmucosal effect and can carry nucleic acids through the nasal mucosa to exert their effects.

[0110] The permeability test results of control example 2.7 show that the fluorescence intensity in the receiving chamber is almost 0 after eight hours, which is close to the test results of control example 2.1 at the corresponding time point. This indicates that the mixed solution of SCS and Moderna LNP cannot achieve transmucosal nucleic acid delivery. On the other hand, it also indicates that if the modified chitosan is not modified on the surface of the liposome, it cannot help the liposome to penetrate the nasal mucosa, which indirectly proves that the modified chitosan and the anionic liposome are combined through electrostatic interaction and play a role in promoting permeation during the transmucosal process.

[0111] Example 3: Evaluation of transfection efficiency of modified chitosan-modified liposome nanoparticles in nasal mucosa

[0112] Liposome nanoparticles loaded with mRNA expressing green fluorescent protein (GFP) were prepared according to the concentration ratio described in Example 1.3.1 and Example 1.3.4, and the mixture was administered to mice by nasal drops. The mice were sacrificed 24 hours after administration, and the nasal tissues of the mice were collected, fixed overnight with 4% paraformaldehyde, and decalcified in a decalcification solution (10% EDTA, PH 7.4) for 7 days. After decalcification, the sections were embedded and the fluorescence intensity of the samples was observed by fluorescence confocal microscopy.

[0113] Example 3.1: SCS-LNP loaded with mRNA expressing GFP prepared using the concentration ratio of Example 1.3.1 was administered by nasal drops;

[0114] Example 3.2: SCS-LNP loaded with mRNA expressing GFP prepared using the concentration ratio of Example 1.3.4 was administered by nasal drops. The dosage was the same as that of Example 3.1, based on the amount of mRNA.

[0115] Figure 3 It is a confocal microscopic image superimposed with a fluorescent image and a fluorescent bright field. It can be seen that the green fluorescence in the mouse nasal cavity of Example 3.2 is significantly higher than that of Example 3.1. The increase in green fluorescence intensity indicates that the liposome nanoparticles delivered the mRNA expressing GFP and successfully transfected the cells, causing the cells to express GFP and thus increase the fluorescence intensity. The results of Example 3 show that the liposome nanoparticles modified with modified chitosan can deliver mRNA through the nasal mucosa, have high delivery and transfection efficiency, and can effectively activate the mucosal immune system.

[0116] Example 4: In vitro transfection efficiency of modified chitosan-modified liposome nanoparticles

[0117] Human nasal septum epithelial cells (human nasal epithelial cells) RPMI2650 were inoculated in a 96-well plate. Different samples were added to each well after the cells adhered to the wall. After 12 hours of co-culture, the culture medium was removed, and the plates were washed 2-3 times with PBS. Lysis buffer was added to lyse the cells, and luciferase substrate was added to measure the bioluminescence intensity on a microplate reader.

[0118] The samples incubated with cells in each embodiment are as follows:

[0119] Control Example 4.1: A blank control group without any sample added;

[0120] Control Example 4.2: Free mRNA sequence (mLUC) with luciferase (LUC) gene fragment;

[0121] Control Example 4.3: Liposome nanoparticles prepared according to the method described in Example 1.1, wherein the loaded mRNA is mLUC;

[0122] Control Example 4.4: Commercial liposomes prepared according to the method described in Control Example 1.4, wherein the loaded mRNA is mLUC;

[0123] Examples 4.5 to 4.9 correspond to the modified chitosan-modified liposome nanoparticles prepared at the mass ratios described in Examples 1.3.2 to 1.3.6, respectively, except that the mRNA loaded therein is mLUC;

[0124] The addition amount of each group of samples in Control Example 4.1 to Example 4.9 was the same, which was 0.5 μg / mL (based on mLUC mass).

[0125] When mLUC is taken up by cells and translated into protein in cells, luciferase (LUC) as a reporter gene can be used to quantify the expression level through its bioluminescence characteristics to evaluate the in vitro transfection efficiency of each group of samples. Figure 4 As shown in the results, the bioluminescence intensity of the cells in Examples 4.6 to 4.8 increased significantly, indicating that the modification of modified chitosan improved the transfection efficiency of liposome nanoparticles and further improved the cell uptake of mRNA and the expression of corresponding proteins.

[0126] Example 5: Evaluation of the efficacy of intranasal administration of modified chitosan-modified liposome nanoparticles for enhancing immunity

[0127] Example 5.1: Effect of intranasal administration of modified chitosan-modified liposome nanoparticles on humoral immunity

[0128] Healthy Balb / c mice were divided into groups after adaptive feeding, and different samples were used to vaccinate each group of mice. The dosage was calculated based on mRNA (mOVA), and each mouse was given 5 μg. The antibody titer in the peripheral blood of mice was detected on the 7th day after administration. The specific detection process was as follows: the peripheral blood of mice was centrifuged at 5000 rpm for 5 minutes to separate serum and blood cells, and the mouse serum was diluted and the OVA-specific IgG antibody level was detected by enzyme-linked immunosorbent assay (ELISA).

[0129] The embodiments are grouped as follows:

[0130] Control 5.1.1: Untreated healthy mice;

[0131] Example 5.1.2: Using Moderna commercial liposomes prepared according to the method described in Control Example 1.4 to treat mice, wherein the mRNA loaded in the commercial liposomes is mOVA, and the treatment method is intramuscular injection;

[0132] Example 5.1.3: Treating mice with liposome nanoparticles prepared according to the method described in Example 1.1, wherein the mRNA loaded in the liposome nanoparticles is mOVA, and the treatment method is intramuscular injection;

[0133] Example 5.1.4: Using the modified chitosan-modified liposome nanoparticles prepared by the method described in Example 1.3.4 to treat mice, wherein the mRNA loaded by the modified chitosan-modified liposomes is mOVA, and the treatment method is intranasal administration;

[0134] The OVA-specific IgG antibody titer endpoint of each group of mice in Example 5.1.2 to Example 5.1.4 was evaluated using the mice in Control Example 5.1.1 as the background. The results are as follows Figure 5 As shown. Antibody titer is used to measure the minimum concentration (i.e., maximum dilution) required for a certain antibody to recognize a specific antigenic determinant, and is generally expressed as the maximum dilution that can still produce a positive result. Antibody titer is used to evaluate the level of antigen-specific antibodies against OVA produced by mice after immunization. The results show that the dilution multiples when each group of Example 5.1.2-Example 5.1.4 can detect IgG antibody positivity are close, indicating that the antibody concentrations in the peripheral blood of each group after vaccination are close. Commercial liposomes require intravenous or intramuscular injection. The immune effect achieved by the modified chitosan-modified liposome nanoparticles described in this application through nasal administration is close to that of commercialized liposomes injected intramuscularly, and the effect is better. The modified chitosan-modified liposome nanoparticles described in this application can be administered by nasal drops, and its method of use is simple, and patient compliance is high, and it has great development potential.

[0135] Antibodies are key effector molecules in humoral immune responses. They can specifically recognize and bind to antigens, exerting biological effects such as neutralization, agglutination, and precipitation. The above experimental results show that nasal administration of the modified chitosan-modified liposome nanoparticles described in the present application can transfect somatic cells and express the mRNA fragments they carry, thereby inducing a humoral immune response in the body, producing a large number of specific antibodies, and providing protection for the body.

[0136] Example 5.2: Effect of intranasal administration of modified chitosan-modified liposome nanoparticles on cellular immunity

[0137] Healthy Balb / c mice were divided into groups after adaptive feeding, and each group of mice was vaccinated with different samples. The dosage was calculated based on mRNA (mOVA), 5 μg / time for each mouse, once every 7 days, for a total of 3 times.

[0138] The samples were grouped according to the scheme of Example 5.1 and numbered as Control Example 5.2.1, Example 5.2.2, Example 5.2.3, and Example 5.2.4.

[0139] The first administration was recorded as day 0. The mice were killed on day 28, and the spleens were collected and the interferon-γ (IFN-γ)-positive CD4 + Helper T cells (CD3 + CD4 + IFN-γ + ) and the relative content of interferon-γ (IFN-γ) positive CD8 + Cytotoxic T cells (CD3 + CD8 + IFN-γ + ) relative content; the results are as follows Figure 6 , Figure 7 The results showed that compared with the control example 5.2.1, the IFN-γ positive CD4 + Helper T cells, IFN-γ positive CD8 + The relative content of cytotoxic T cells increased significantly. IFN-γ is a multifunctional cytokine that is mainly produced by activated CD4 + T cells and CD8 + T cells are produced, which can activate a variety of immune cells and enhance immune response. IFN-γ positive CD8 + T cells and CD4 + Helper T cells can enhance the activity of antigen presenting cells and promote the functions of other immune cells such as macrophages and dendritic cells by secreting IFN-γ. Therefore, the above results show that the nasal administration of the modified chitosan-modified liposome nanoparticles described in this application can also stimulate the body's powerful cellular immunity, thereby playing an important role in the antiviral and anti-tumor process.

[0140] Example 5.3: Effect of intranasal administration of modified chitosan-modified liposome nanoparticles on mucosal immunity

[0141] The mRNA sequence (mOVA) carrying the chicken ovalbumin (OVA) gene fragment was selected for research: healthy Balb / c mice were grouped after adaptive feeding, and the mice were vaccinated with samples from each group. The dosage was calculated as mOVA, 5 μg per mouse per time, once every 7 days, for a total of 3 times.

[0142] The samples were grouped according to the scheme of Example 5.1 and numbered as Control Example 5.3.1, Example 5.3.2, Example 5.3.3, and Example 5.3.4.

[0143] The first administration was recorded as day 0. The mice were killed on day 28, and the nasal mucosal lavage fluid of the mice was collected to detect the antibody titer of OVA-specific secretory IgA (sIgA). The results are as follows: Figure 8 As shown. Compared with Example 5.3.2, the OVA-specific sIgA antibody titer values ​​of each group of mice in Example 5.3.3-Example 5.3.4 increased significantly, indicating that the modified chitosan-modified liposome nanoparticles can be retained in the nasal cavity after nasal administration, transfect nasal epithelial cells and further induce a strong mucosal immune response. sIgA is the main antibody on the mucosal surface and constitutes one of the main components of the mucosal immune system. It protects the body from infection by specifically binding to pathogens, preventing pathogens from adhering to and penetrating the mucosal layer. The above results show that the modified chitosan-modified liposome nanoparticles described in this application can enhance the protection and regulation of mucosal immunity and improve the body's resistance by nasal administration.

[0144] In summary, the modified chitosan-modified liposome nanoparticles described in the present application can induce a triple immune response of humoral, cellular, and mucosal, which is similar to the response efficiency of commercial liposomes injected intramuscularly. The nasal drop administration method has unique advantages over traditional intramuscular injection and has great potential for vaccine development and commercialization.

[0145] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.

Claims

1. A modified liposome, characterized in that: The outer surface of the liposome is modified with modified chitosan, the liposome is an anionic liposome, and the modified chitosan is obtained by connecting sodium 8-(2-hydroxybenzamido)octanoate and chitosan through an amide bond.

2. The modified liposome according to claim 1, characterized in that The mass ratio of the anionic liposome to the modified chitosan is 1:0.5-2.

3. The modified liposome according to claim 1, characterized in that The anionic liposomes are composed of anionic lipids, phospholipids, polyethylene glycol lipids and cholesterol. Taking the molar percentage of the anionic lipids, phospholipids, polyethylene glycol lipids and cholesterol as 100 mol%, the proportion of each component is 5 mol%-15 mol%, 20 mol%-80 mol%, 0 mol%-5 mol%, and 10 mol%-50 mol%.

4. The method for preparing the modified liposome according to any one of claims 1 to 3, characterized in that: The following steps are involved: S1. preparing liposomes; S2, mixing chitosan with activated sodium 8-(2-hydroxybenzamido)octanoate to obtain modified chitosan; S3, mixing the liposome obtained in S1 with the modified chitosan obtained in S2 to obtain the modified liposome.

5. Use of the modified liposome according to any one of claims 1 to 3 in the preparation of a mucosal vaccine, characterized in that: The mucosa is the nasal mucosa.

6. A delivery carrier for nasal drugs, characterized in that: The delivery vehicle comprises the modified liposome according to any one of claims 1-3.

7. A nucleic acid vaccine, characterized in that: The nucleic acid vaccine contains nucleic acid and the modified liposome according to any one of claims 1 to 3.

8. The nucleic acid vaccine according to claim 7, characterized in that The preparation method of the nucleic acid vaccine is: (1) preparing an aqueous phase solution and a lipid phase solution containing nucleic acid, and preparing liposomes with the aqueous phase solution and the lipid phase solution; (2) mixing chitosan with activated sodium 8-(2-hydroxybenzamido)octanoate to obtain modified chitosan; (3) Mixing the liposomes and the modified chitosan to obtain the nucleic acid vaccine.

9. The nucleic acid vaccine according to claim 7, characterized in that In the nucleic acid vaccine, the mass ratio of the modified liposome to the nucleic acid is 10-200:

1.

10. A drug for preventing or treating infectious diseases, characterized in that: The medicine contains the modified liposome according to any one of claims 1 to 3, the delivery vector according to claim 6 or the nucleic acid vaccine according to any one of claims 7 to 9.